How Much Does Pharmaceutical Research & Manufacturers of America Spend on Lobbying?

Pharmaceutical Research & Manufacturers of America's disclosed federal lobbying spend of $135.8M places it in the megaspender tier — the small set of organizations that have crossed nine figures in cumulative reported lobbying outlays. Spending at this scale typically means a permanent in-house government affairs office, a roster of outside lobbying firms on retainer, and active engagement on dozens of separate policy items in any given year.

Pharmaceutical Research & Manufacturers of America's disclosed lobbying covers 9 general issue areas — a moderate footprint. Filers in this range tend to engage on a coherent cluster of related topics rather than spreading effort across the federal agenda.

The Senate Lobbying Disclosure Act requires anyone who contacts covered federal officials on behalf of a paying client — and crosses time and dollar thresholds — to register and file quarterly. Filings are publicly available through the Senate Office of Public Records, which is the original source for every dollar figure on this page. The same filings feed downstream research at OpenSecrets, where you can cross-reference individual lobbyists, bills tracked, and related campaign contributions.

14 of 60 lobbyists reported by Pharmaceutical Research & Manufacturers of America (23%) disclose prior federal government service — a small minority of the named bench.

Among the named bench, lobbyists with disclosed prior federal service include Margaret M. Taylor (Former Deputy Secretary of Defense); Sarah L. Johnson (Former Legislative Assistant, U.S. Senate); Michelle K. Collins (Former Deputy Secretary of Defense). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.

Within the Pharmaceutical & Health Products sector, Pharmaceutical Research & Manufacturers of America ranks #0 of 33 tracked organizations by disclosed lobbying spend. The sector leader is Pfizer Inc at $54.4M; the sector average is $13.1M. Pharmaceutical Research & Manufacturers of America's $135.8M sits 935% above the sector average.

Pharmaceutical Research & Manufacturers of America's LobbySpend Influence Score of 69/100 (grade B) reflects significant federal lobbying reach. The score blends disclosed total spend, issue breadth, and revolving-door connections — lobbyists with prior federal government service. A B-grade typically means the organization is well above average on at least two of those three signals, with sustained activity over multiple years rather than a one-off spike.

Across the 5-year window from 2020 to 2024, Pharmaceutical Research & Manufacturers of America's annual disclosed lobbying spend has declined modestly — from $25.9M in 2020 to $24.6M in 2024, a change of -5%. Step-changes of this size often coincide with major bills moving through Congress, regulatory rulemakings affecting the organization's industry, or a leadership change in the relevant committee.

Every dollar on this page comes from quarterly filings submitted under the Lobbying Disclosure Act and published by the Senate Office of Public Records. We pull those filings via the lda.senate.gov public API, deduplicate amendments, and aggregate by registrant or client across the years shown. The "amount" for each filing is the larger of reported income (for lobbying firms) or reported expenses (for in-house programs), which is the standard convention used by both the Senate's own dashboards and outside researchers including OpenSecrets.

The LobbySpend Influence Score is a composite indicator: 40% disclosed total spend, 30% number of distinct general issue areas lobbied on, and 30% share of named lobbyists with prior federal government service. The score is descriptive — it summarizes what was disclosed — and should not be read as a measure of effectiveness, ethics, or political outcomes. Read the full methodology for the exact formulas, caveats, and known limitations of LDA disclosures.